Stramkauskaitė Almina, Povilaitytė Ieva, Glebauskienė Brigita, Liutkevičienė Rasa
Department of Ophthalmology, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania.
Neuroscience Institute, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania.
Acta Med Litu. 2022;29(1):9-18. doi: 10.15388/Amed.2022.29.1.19. Epub 2022 Jun 29.
Leber hereditary ptic neuropathy (LHON) is a disease of young adults with bilateral, painless, subacute visual loss. The peak age of onset of LHON is in the second and third decades of life. Men are 4 times more likely to be affected than women. In about 25-50% of cases, both eyes are affected simultaneously. In unilateral cases, the other eye is usually affected 2 to 3 months later. Visual acuity deteriorates to counting fingers or worse with a dense central or centrocecal scotoma. In the subacute phase, the optic disc may appear hyperemic with swelling of the peripapillary retinal nerve fibre layer, peripapillary telangiectasias, and increased vascular tortuosity. Ocular coherence tomography of the macula shows marked thinning of the ganglion cell complex even at this stage. The diagnosis of LHON is made in a subject with a consistent clinical history and/or one of three common pathogenic mitochondrial DNA (mtDNA) variants identified by molecular genetic testing. Idebenone was approved by the European Medicines Agency under exceptional circumstances for the treatment of LHON. Current evidence suggests some benefit to vision in a subset of affected individuals treated with idebenone, particularly when treated within the first year of onset of vision loss. In this article, we discuss aetiology, clinical features, diagnosis, differential dignosis, prognosis and treatment.
Leber遗传性视神经病变(LHON)是一种发生于年轻人的疾病,表现为双侧无痛性亚急性视力丧失。LHON的发病高峰年龄在20至30岁之间。男性受影响的可能性是女性的4倍。在约25%至50%的病例中,双眼同时受累。在单侧病例中,另一只眼通常在2至3个月后受累。视力下降至仅能数指或更差,伴有致密的中心或中心暗点。在亚急性期,视盘可能充血,视乳头周围视网膜神经纤维层肿胀,视乳头周围毛细血管扩张,血管迂曲增加。即使在此阶段,黄斑的光学相干断层扫描也显示神经节细胞复合体明显变薄。LHON的诊断基于具有一致临床病史的患者和/或通过分子基因检测鉴定出的三种常见致病性线粒体DNA(mtDNA)变异之一。艾地苯醌在特殊情况下被欧洲药品管理局批准用于治疗LHON。目前的证据表明,在一部分接受艾地苯醌治疗的受影响个体中,视力有一定益处,尤其是在视力丧失发病的第一年内接受治疗时。在本文中,我们讨论了病因、临床特征、诊断、鉴别诊断、预后和治疗。